Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Sees Strong Trading Volume – Should You Buy?

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) saw unusually-strong trading volume on Tuesday . 1,500 shares changed hands during mid-day trading, an increase of 384% from the previous session’s volume of 310 shares.The stock last traded at $48.2050 and had previously closed at $49.0282.

Wall Street Analyst Weigh In

Several research firms have commented on BIOVF. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Swedish Orphan Biovitrum in a report on Tuesday, July 21st. Pareto Securities lowered shares of Swedish Orphan Biovitrum to a “hold” rating in a report on Monday, June 29th. Zacks Research raised shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, May 7th. HC Wainwright assumed coverage on shares of Swedish Orphan Biovitrum in a report on Wednesday, May 6th. They issued a “buy” rating for the company. Finally, Barclays reaffirmed an “overweight” rating on shares of Swedish Orphan Biovitrum in a research report on Friday, July 3rd. Four investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

Swedish Orphan Biovitrum Price Performance

The company has a market capitalization of $17.16 billion, a price-to-earnings ratio of 107.12 and a beta of 0.35. The company has a quick ratio of 0.47, a current ratio of 0.70 and a debt-to-equity ratio of 0.19. The firm has a 50 day moving average price of $48.17 and a two-hundred day moving average price of $42.95.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.38 by $0.07. Swedish Orphan Biovitrum had a return on equity of 18.27% and a net margin of 4.74%.The business had revenue of $755.76 million for the quarter, compared to analysts’ expectations of $749.76 million. As a group, sell-side analysts expect that Swedish Orphan Biovitrum will post 1.94 earnings per share for the current year.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.